ClinVar Miner

Submissions for variant NM_000155.4(GALT):c.1132A>G (p.Ile378Val) (rs111033819)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000507865 SCV000603800 uncertain significance not specified 2017-02-16 criteria provided, single submitter clinical testing
Counsyl RCV000022280 SCV000800504 uncertain significance Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2017-03-06 criteria provided, single submitter clinical testing
Invitae RCV000022280 SCV000965232 uncertain significance Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2018-09-24 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with valine at codon 378 of the GALT protein (p.Ile378Val). The isoleucine residue is weakly conserved and there is a small physicochemical difference between isoleucine and valine. This variant is present in population databases (rs111033819, ExAC 0.02%). This variant has been observed in an individual affected with galactosemia (PMID: 11678552). ClinVar contains an entry for this variant (Variation ID: 25334). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Illumina Clinical Services Laboratory,Illumina RCV000022280 SCV001331420 uncertain significance Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2017-04-28 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Research and Development, ARUP Laboratories RCV000022280 SCV000042965 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001354665 SCV001549335 uncertain significance not provided no assertion criteria provided clinical testing The GALT p.Ile269Val variant was identified in 1 of 154 proband chromosomes (frequency: 0.0065) from patients with galactosaemia (Zekanowski_2001_PMID:11678552). The variant was identified in dbSNP (ID: rs111033819) and ClinVar (classified as uncertain significance by ARUP Laboratories, Counsyl and Invitae, and as pathogenic by Research and Development, ARUP Laboratories). The variant was identified in control databases in 31 of 282716 chromosomes at a frequency of 0.0001097 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 27 of 129094 chromosomes (freq: 0.000209), European (Finnish) in 3 of 25098 chromosomes (freq: 0.00012) and Ashkenazi Jewish in 1 of 10360 chromosomes (freq: 0.000097), but was not observed in the African, Latino, East Asian, Other or South Asian populations. The p.Ile269 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.